The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection

AIDS

Volumn 13, Issue 3, 1999, Pages 415-418

  Paul, Simon ^a   Gilbert, Holly M ^b   Ziecheck, Wendy ^a   Jacobs, Jonathan ^a   Sepkowitz, Kent A ^a,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AIDS; Antiretroviral therapy; CD4 cells; Epidemiology; HIV infection; Hospitalization; Opportunistic infection

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ARTICLE; BACTERIAL PNEUMONIA; FEMALE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LENGTH OF STAY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OUTPATIENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; UNITED STATES;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; NEW YORK CITY; TREATMENT OUTCOME;

EID: 0033043348     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199902250-00015     Document Type: Article

References (13)

1. Mouton Y, Alfandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-F105.
2. Moore RD, Keruly JC, Chaisson RE: Effectiveness of combination antiretroviral therapy in clinical practice. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September-October 1997 [abstract 1-176].
3. Flexner C: Drug therapy: HIV protease inhibitors. N Engl J Med 1998, 338:1281-1292.
4. Centers for Disease Control and Prevention: Update: trends in AIDS incidence, deaths and prevalence - United States, 1996. MMWR 1997, 46:861-867.
5. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
6. Gebhardt M, Rickenbach M, Egger M, et al.: Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. AIDS 1998, 12:1195-1201.
7. Fleming PL, Ward JW, Karon JM, Hanson DL, De Cock KM: Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998, 12 (suppl A):S55-S61.
8. Centers for Disease Control. 1993 Revised HIV classification system and expanded AIDS surveillance definition for adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
9. Keiser P, Kvanii M, Turner D, Smith JW, Nassar NN, Gregg CR: Decreased hospital utilization and costs are associated with protease inhibitor therapy but not with nucleoside therapy. Fifth Conference of Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 204].
10. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
11. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
12. Chaisson MA, Berenson L, Schwartz S, Singh T, Forlenza S, Mojica B: Accelerating decline in New York City AIDS mortality. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 9b].
13. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.